Breast Cancer Screening: Expected and Observed Incidence and Stages of Female Breast Cancer in Gävleborg County, Sweden, and Implications for Mortality

Author(s):  
B. Lundgren
PLoS ONE ◽  
2017 ◽  
Vol 12 (7) ◽  
pp. e0180696 ◽  
Author(s):  
Tam Truong Donnelly ◽  
Al-Hareth Al-Khater ◽  
Salha Bujassoum Al-Bader ◽  
Mohamed Ghaith Al-Kuwari ◽  
Mariam Ali Abdul Malik ◽  
...  

2020 ◽  
Author(s):  
Talha Tahir ◽  
Melanie Mitsui Wong ◽  
Rabia Tahir ◽  
Michael Mitsui Wong

AbstractIntroductionMammography-based breast cancer screening is an important aspect of female breast cancer prevention within the Canadian healthcare system. The current literature on female breast cancer screening is largely focused on the health outcomes that result from screening. There is comparatively little data on the cost-effectiveness of the screening. Therefore, this paper sought to conduct a systematic review of the literature on the cost effectiveness of mammography-based breast cancer screening within female Canadian populations.Materials and methodsA systematic review was performed in the PubMed database to identify all studies published within the last 10 years that addressed breast cancer screening and evaluate cost-effectiveness in a Canadian population.ResultsThe search yielded five studies for inclusion, only three of which were applicable to average-risk Canadian women. The benefits of mortality reduction rose approximately linearly with costs, while costs were linearly dependent on the number of lifetime screens per woman. Moreover, triennial screening for average-risk women aged 50-69 years was found to be the most cost-effective in terms of cost per quality adjusted life year. The use of MRI in conjunction with mammography for women with the BRCA 1/2 mutation was found to be cost-effective while annual mammography-based screening for women with dense breasts was found to be cost-ineffective.ConclusionIn spite of the growing interest to enhance breast cancer screening programs, analyses of the cost-effectiveness of mammography-based screening within Canadian populations are scarcely reported and have heterogeneous methodologies. The existing data suggests that Canada’s current breast cancer screening policy to screen average-risk women aged 50-74, biennially or triennially is cost-effective. These findings could be of interest to health policy makers when making decisions regarding resource allocation; however, further studies in this field are required in order to make stronger recommendations regarding cost-effectiveness.


2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 146-146
Author(s):  
Xingran Weng ◽  
Chan Shen ◽  
Monali Vasekar ◽  
Sachin Gupta ◽  
Li Wang

Abstract Background: Incidence of both breast cancer and Alzheimer’s disease and related dementias (ADRD) increases with advancing age. Little research has delineated breast cancer screening, diagnosis, and treatment among women with ADRD. Method: Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data were used. Female breast cancer patients diagnosed between 2005-2015 were identified. Chi-square tests were conducted to compare the characteristics of two groups with and without ADRD. Multiple logistic regression models were estimated to explain the diagnosis and treatment differences. Results: A total of 44,112 female Medicare beneficiaries age 65 or older were identified. Patients with ADRD (17.5%) were less likely to receive breast cancer screening (42.8% vs. 46.6% for all data years combined, p<0.0001), more likely to be diagnosed with breast cancer after death by autopsy or death certificate (8.1% vs 2.0%, p<0.0001). Among those who are diagnosed before death, patients with ADRD were more likely to be diagnosed with breast cancer at age 75 and older (84.8% vs. 15.2%, p<0.0001). After adjusting for age, race, poverty level, marital status, cancer stage at diagnosis, cancer screening history, wellness visit history, comorbidity, and rural/urban residence, logistic regressions suggest that patients with ADRD were less likely to receive surgery (AOR=0.48, 95%CI: 0.45-0.52), radiation (AOR=0.41, 95%CI: 0.39-0.44), or chemotherapy (AOR=0.38, 95%CI: 0.35-0.41). Conclusion: Breast cancer screening was less utilized and breast cancer was diagnosed at an older age in patients with ADRD than those without. Treatments (surgery, radiation, and chemotherapy) were given less frequently to patients with ADRD.


2019 ◽  
Vol 25 ◽  
pp. 201-202
Author(s):  
Mary Stevenson ◽  
Robert Sineath ◽  
Michael Goodman ◽  
Vin Tangpricha

Sign in / Sign up

Export Citation Format

Share Document